Chun-Ying Wu1, Yao-Chun Hsu2, Hsiu J Ho3, Yi-Ju Chen4, Teng-Yu Lee3, Jaw-Town Lin5. 1. Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine and Graduate Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan Department of Public Health and Graduate Institute of Clinical Medical Sciences, China Medical University, Taichung, Taiwan National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan Department of Life Sciences and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan. 2. Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan. 3. Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan. 4. Faculty of Medicine and Graduate Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 5. Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan School of Medicine, Fu Jen Catholic University, Taipei, Taiwan Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
Abstract
OBJECTIVE: Current guidelines recommend screening for hepatocellular carcinoma (HCC) in high-risk populations. However, the effectiveness of screening in reducing mortality has been challenged. In addition, it is unclear which subgroups benefit most from HCC screening. DESIGN: This nationwide cohort study identified a total of 52,823 newly diagnosed HCC patients between 1 January 2002 and 31 December 2007. These HCC patients were classified into the following cohorts according to the time intervals in which they received ultrasonography screening: 0-6 months (6M), 7-12 months (12M), 13-24 months (24M), 25-36 months (36M) and not screened within 3 years (never screened). The chance to receive curative therapy and 5-year cumulative mortalities were calculated after adjusting for lead-time bias. RESULTS: Chances to receive curative therapy among the 6M, 12M, 24M, 36M and never screened cohorts were 24.3% (95% CI 23.7% to -24.9%), 26.9% (95% CI 25.7% to 28.2%), 22.9% (95% CI 21.8% to 24.1%), 21.3% (95% CI 19.9% to 22.8%) and 18.3% (95% CI 17.8% to 18.8%), respectively. Compared with the 6M cohort, adjusted HRs of mortality for the 12M, 24M, 36M and never screened cohorts were 1.11 (95% CI 1.07 to 1.15), 1.23 (95% CI 1.19 to 1.28), 1.31 (95% CI 1.26 to 1.37) and 1.47 (95% CI 1.43 to 1.51) (all p<0.001), respectively. On multivariable subgroup analyses, the associations between shorter screening intervals and better survival were observed in nearly all subgroups, especially in younger patients, patients without diabetes and patients with hepatitis B infection. CONCLUSIONS: Shorter ultrasonography screening intervals are associated with reduced overall mortality in HCC patients in a dose-dependent manner. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Current guidelines recommend screening for hepatocellular carcinoma (HCC) in high-risk populations. However, the effectiveness of screening in reducing mortality has been challenged. In addition, it is unclear which subgroups benefit most from HCC screening. DESIGN: This nationwide cohort study identified a total of 52,823 newly diagnosed HCC patients between 1 January 2002 and 31 December 2007. These HCC patients were classified into the following cohorts according to the time intervals in which they received ultrasonography screening: 0-6 months (6M), 7-12 months (12M), 13-24 months (24M), 25-36 months (36M) and not screened within 3 years (never screened). The chance to receive curative therapy and 5-year cumulative mortalities were calculated after adjusting for lead-time bias. RESULTS: Chances to receive curative therapy among the 6M, 12M, 24M, 36M and never screened cohorts were 24.3% (95% CI 23.7% to -24.9%), 26.9% (95% CI 25.7% to 28.2%), 22.9% (95% CI 21.8% to 24.1%), 21.3% (95% CI 19.9% to 22.8%) and 18.3% (95% CI 17.8% to 18.8%), respectively. Compared with the 6M cohort, adjusted HRs of mortality for the 12M, 24M, 36M and never screened cohorts were 1.11 (95% CI 1.07 to 1.15), 1.23 (95% CI 1.19 to 1.28), 1.31 (95% CI 1.26 to 1.37) and 1.47 (95% CI 1.43 to 1.51) (all p<0.001), respectively. On multivariable subgroup analyses, the associations between shorter screening intervals and better survival were observed in nearly all subgroups, especially in younger patients, patients without diabetes and patients with hepatitis B infection. CONCLUSIONS: Shorter ultrasonography screening intervals are associated with reduced overall mortality in HCC patients in a dose-dependent manner. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Shari S Rogal; Vera Yakovchenko; Rachel Gonzalez; Angela Park; Lauren A Beste; Karine Rozenberg-Ben-Dror; Jasmohan S Bajaj; Dawn Scott; Heather McCurdy; Emily Comstock; Michael Sidorovic; Sandra Gibson; Carolyn Lamorte; Anna Nobbe; Maggie Chartier; David Ross; Jason A Dominitz; Timothy R Morgan Journal: Cancers (Basel) Date: 2021-05-07 Impact factor: 6.639